Paul A Moore

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 2

Top Topics

Photodynamic Therapy

Magnetic Resonance

Top Venues

Nature medicine

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Jason John Luke, Manish R Patel, George R Blumenschein, Erika Paige Hamilton, Bartosz Chmielowski, Susanna V Ulahannan, Roisin M Connolly, Cesar A Santa-Maria, Jie Wang, Shakeela W Bahadur, Andrew Weickhardt, Adam S Asch, Girish Mallesara, Philip Clingan, Monika Dlugosz-Danecka, Monika Tomaszewska-Kiecana, Halyna Pylypenko, Nada Hamad, Hedy L Kindler, Bradley J Sumrow, Patrick Kaminker, Francine Z Chen, Xiaoyu Zhang, Kalpana Shah, Douglas H Smith, Anushka De Costa, Jonathan Li, Hua Li, Jichao Sun, Paul A Moore
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nature medicine (2023)
Juniper A Scribner, Stuart W Hicks, Kerstin W Sinkevicius, Nicholas C Yoder, Gundo Diedrich, Jennifer G Brown, Jacquelynn Lucas, Megan E Fuller, Thomas Son, Anahita Dastur, Jeff Hooley, Christopher Espelin, Marian Themeles, Francine Z Chen, Ying Li, Michael Chiechi, Jenny Lee, Bhaswati Barat, Lusiana Widjaja, Sergey Gorlatov, James Tamura, Valentina Ciccarone, Olga Ab, Kerry A McEachem, Scott Koenig, Eric H Westin, Paul A Moore, Thomas Chittenden, Richard J Gregory, Ezio Bonvini, Deryk Loo
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. Molecular cancer therapeutics 21 (7) (2022)